Ney Carter Borges/LinkedIn
Apr 26, 2026, 11:38
Ney Carter Borges: Perioperative Cardiovascular Medication Management in Noncardiac Surgery
Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared a post on LinkedIn:
“Perioperative Cardiovascular Medication Management (Noncardiac Surgery)
Key Clinical Recommendations (AHA/ACC 2024 Guideline – JAMA 2026)
Statins
- Continue therapy perioperatively
- Initiate in high-risk patients
- Decreased mortality: 2.18% vs 3.15% (OR 0.62; 95% CI 0.58–0.67)
Aspirin
- Continue if prior PCI
- Do NOT initiate without PCI
- Increased bleeding risk: 4.6% vs 3.8% (HR 1.23; p equals 0.04)
β-blockers
- Continue if already prescribed
- Avoid initiation perioperatively
- Increased mortality: HR 1.33 (95% CI 1.03–1.74)
SGLT2 inhibitors
- Suspend before surgery
- 3 days: dapagliflozin / empagliflozin
- 4 days: ertugliflozin
- Reason: risk of euglycemic ketoacidosis
GLP-1 receptor agonists
- Consider withholding (depending on case)
- Risk: delayed gastric emptying – aspiration
- Gastric residue: 11 vs 1 (p equals 0.004).”

Other posts featuring Ney Carter Borges on Hemostasis Today.
-
Jun 14, 2026, 22:49Cihan Ay: From First Oral Presentation to Pro and Con Debate – A 20-Year EHA Journey
-
Jun 14, 2026, 19:54Tareq Abadl: What Happens If You Transfuse the Wrong Blood Group?
-
Jun 14, 2026, 19:46Amber Yates: Stretching Scientific Muscles in Areas of Hematology – Day 2 at EHA 2026
-
Jun 14, 2026, 19:41Peter Loffelhardt: Thousands of People Coming in – Second Day at EHA 2026
-
Jun 14, 2026, 19:38Jecko Thachil: Can We Predict and Prevent Bleeding in APL?
-
Jun 14, 2026, 19:32Highlights from Day 1 at the EHC Leadership Conference 2026
-
Jun 14, 2026, 18:01Ahmar U. Zaidi: The First Pivotal Study of a New Mechanism in Sickle Cell Disease
-
Jun 14, 2026, 18:00Lennart Lenk: Witnessing Former Boss Deliver a Plenary Talk at EHA 2026
-
Jun 14, 2026, 18:00Priya Sriskandarajah: Great Presentations on Recent Advances in Myelofibrosis at EHA 2026